Bioorganic and Medicinal Chemistry Letters (2019)
Update date:2022-08-04
Topics:
Trzoss, Michael
Covel, Jonathan A.
Kapoor, Mili
Moloney, Molly K.
Soltow, Quinlyn A.
Webb, Peter J.
Shaw, Karen Joy
Fosmanogepix (APX001) is a first-in-class prodrug molecule that is currently in Phase 2 clinical trials for invasive fungal infections. The active moiety manogepix (APX001A) inhibits the novel fungal protein Gwt1. Gwt1 catalyzes an early step in the GPI anchor biosynthesis pathway. Here we describe the synthesis and evaluation of 292 new and 24 previously described analogs that were synthesized using a series of advanced intermediates to allow for rapid analoging. Several compounds demonstrated significantly (8- to 32-fold) improved antifungal activity against both Cryptococcus neoformans and C. gattii as compared to manogepix. Further in vitro characterization identified three analogs with a similar preliminary safety and in vitro profile to manogepix and superior activity against Cryptococcus spp.
View MoreContact:0086 371 65711996
Address:Jalan 4/3, Kawasan Perindustrian Serendah, 48000 Rawang,
ZhangJiaGang YaRui Chemical Co.,Ltd.
Contact:0512-58360968
Address:China JiangSu Province Zhang Jia Gang City YangShe Oriental Plaza Building 10 B307
Luojiang Chenming Biological Products Co
Contact:+86 15000297032
Address:GROUP NO.4, HE SHENG VILLAGE, PANLONG TOWN,
Contact:86-575-86132822,86-575-86085355
Address:No.418 Dadao West Road,Qixing Street,Xinchang, Zhejiang Province, China.
Shuanghe Bio-Technology Limited(expird)
Contact:+86-571-61710758,18968016640
Address:Jinqiao north road 916# Fuyang
Doi:10.1055/s-0036-1588422
(2017)Doi:10.1021/jo01050a549
(1962)Doi:10.1002/chem.200903158
(2010)Doi:10.1016/j.tet.2008.11.103
(2009)Doi:10.1021/acs.orglett.0c04114
(2021)Doi:10.1016/j.bmcl.2007.01.065
(2007)